When was Ikonisys founded?

Ikonisys was founded in 1999 and raised its 1st funding round 8 years after it was founded.

Where is Ikonisys located?

Ikonisys is headquartered in New Haven, United States. It is registered at 5 Science Park, New Haven Connecticut 06511, USA.

How many employees does Ikonisys have?

As of Dec 31, 2021, Ikonisys has 8 employees, reflecting a 15% year-over-year growth in headcount.

Is Ikonisys a funded company?

Ikonisys is a funded company, having raised a total of $35.2M across 6 funding rounds to date. The company's 1st funding round was a $***** Series C round, raised on Oct 17, 2007.

When was the latest funding round of Ikonisys?

Ikonisys' latest funding was a $***** Post IPO round on Feb 27, 2025, with participation from 0 investor. Its primary sector is Oncology. In United States, the Oncology sector has seen $1.23B in funding in 2026 to date.

Where does Ikonisys rank among its competitors?

Ikonisys ranks 65th amongst 432 active competitors, of which 128 are funded. It stands 9th in terms of total funding among its competitors. The most recent competitor to raise funding was Delfi Diagnostics, which secured $34.3M in Dec, 2025.

Who are the top competitors of Ikonisys?

Ikonisys' top competitors include Guardant Health, Natera and Myriad Genetics. Among them, Delfi Diagnostics secured the most recent funding round in December, 2025.

Ikonisys - 2026 Company Profile, Team, Funding & Competitors

Company Details

Developer of non-invasive diagnostic tests for cancer detection. The company has developed oncoFISH for the detection of cancer-related chromosomal abnormalities, oncoFISH bladder for the diagnosis of bladder cancer, oncoFISH cervical, oncoFISH PTEN, and oncoFISH ALK. Also developed a proprietary Ikoniscope digital microscope to deliver highly accurate and reliable detection of rare cells.

Website: ikonisys.com
Registered Address: 5 Science Park, New Haven Connecticut 06511, USA

Key Metrics

Founded Year

1999

Location

New Haven, United States

Stage

Public

Total Funding

$35.2M in 6 rounds

Latest Funding Round

Post IPO, Feb 27, 2025, $*****

Investors

Goldman Sachs & 2 more

Ranked

65^th among 432 active competitors

Employee Count

8 as on Dec 31, 2021

Investment & Acquisitions

Hospitex Diagnostics

Similar Companies

Guardant Health & 556 more

Exit Details

Public

View Ikonisys' full profile

Ikonisys is associated with 1 legal entity given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
IKONISYS, INC. CIN: 06-1560045 , United States, Active	Oct 28, 1999	-	8 (As on Dec 31, 2021)	-

Ikonisys got listed on Jul 19, 2021.

Click here to take a look at Ikonisys's IPO in detail

Ikonisys has raised a total funding of $35.2M over 6 rounds. Its first funding round was on Oct 17, 2007. Ikonisys has 3 institutional investors.

Here is the list of recent funding rounds of Ikonisys:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Feb 27, 2025	2087841	Post IPO	7679427	3095050	1050917	1649926
Nov 19, 2024	9236885	Post IPO	6854718	1923179	6310726	7754822
Dec 28, 2023	1301334	Post IPO	5656401	9625709	4373217	5996435

Access funding benchmarks and valuations. Sign up today!

View details of Ikonisys's funding rounds and investors

The founders of Ikonisys is Michael Kilpatrick.

Here are the details of Ikonisys' key team members:

Michael Kilpatrick: Founder of Ikonisys. They serve on the board of 1 company.
Contact Info: 1 email address

View details of Ikonisys's Founder profiles and Board Members

Ikonisys' employee count trend

Ikonisys has 8 employees as of Dec 21. The total employee count is 14.0% more than what it was in Dec 20. Here is Ikonisys's employee count trend over the years:

Uncover Ikonisys' growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Ikonisys include Guardant Health, Natera and Myriad Genetics. Here is the list of Top 10 competitors of Ikonisys, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Guardant Health 2012, Redwood City (United States), Public	Developer of digital sequencing technology for cancer detection	$557M	SoftBank Vision Fund, Orbimed & 24 others	79/100
2nd	Natera 2004, Redwood City (United States), Public	Developer of cell-free DNA testing for oncology, women’s health, and organ health	$152M	Harmony Partners, Harmony Venture Partners ... & 17 others	77/100
3rd	Myriad Genetics 1991, United States, Public	Developer of molecular diagnostics and personalized medicine for cancer	-	Grayhawk Capital, TriplePoint Capital & 6 others	76/100
4th	Caris Life Sciences 1996, Irving (United States), Public	Developer of panomic disease profiling technologies for cancer precision medicine	$1.23B	Sixth Street, Coatue & 19 others	74/100
5th	Exact Sciences 1995, Madison (United States), Public	Provider of non-invasive molecular diagnostic testing solutions for cancer	-	Petrillo Capital, Bank of America & 8 others	73/100
6th	Foundation Medicine 2010, Cambridge (United States), Acquired	Provider of genomics-based diagnostics test for cancer	$96.5M	Deerfield, Redmile Group & 11 others	71/100
7th	Prenetics 2009, Hong Kong (China), Public	Online platform for genetic and diagnostic health testing that helps identify health risks	$67.6M	Beyond Ventures, Ping An Ventures & 21 others	70/100
8th	BillionToOne 2015, San Francisco (United States), Public	Provider of cell-free cancer liquid biopsy test	$389M	Hummingbird Ventures, Adams Street Partners ... & 29 others	69/100
9th	Delfi Diagnostics 2019, Baltimore (United States), Series B	Provider of DNA sequencing for cancer detection	$332M	DFJ Growth, Orbimed & 18 others	68/100
10th	Foresight Diagnostics 2020, Aurora (United States), Acquired	Developer of minimally-invasive liquid biopsy test for the detection of cancer	$104M	Foresite Capital, Civilization Ventures & 6 others	66/100
65th	Ikonisys 1999, New Haven (United States), Public	Developer of non-invasive diagnostic tests for cancer detection	$35.2M	Goldman Sachs, New Science Ventures & 1 others	47/100